Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 19.5 mg - kyleena is indicated to prevent pregnancy for up to 5 years. replace the system after 5 years if continued use is desired. the use of kyleena is contraindicated when one or more of the following conditions exist: the use of kyleena is contraindicated in pregnancy or with a suspected and kyleena may cause adverse pregnancy outcomes [see contraindications (4), warnings and precautions (5.1, 5.2)]. if a woman becomes pregnant with kyleena in place, the likelihood of ectopic pregnancy is increased and there is an increased risk of miscarriage, sepsis, premature labor, and premature delivery. remove kyleena, if possible, if pregnancy occurs in a woman using kyleena. if kyleena cannot be removed, follow the pregnancy closely [see warnings and precautions (5.1, 5.2)] . there have been isolated cases of virilization of the external genitalia of the female fetus following local exposure to lng during pregnancy with an lng ius in place. animal reproduction studies have not been conducted with kyleena. published studi

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 212.6 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride 80 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 2 mg in 1 ml

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride 80 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - ferumoxides (unii: g6n3j05w84) (iron - unii:e1uol152h7) - solution - 11.2 mg in 1 ml - feridex i.v. is indicated for i.v. administration as an adjunct to mri (in adult patients) to enhance the t2 weighted images used in the detection and evaluation of lesions of the liver that are associated with an alteration in the res. feridex i.v. is contraindicated in patients with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations.

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonate® is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. patients should be instructed to use desonate for the minimum amount of time as necessary to achieve the desired results because of the potential for desonate to suppress the hypothalamic-pituitary-adrenal (hpa) axis [see warnings and precautions (5.1)] . treatment should not exceed 4 consecutive weeks [see dosage and administration (2)]. desonate is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. there are no adequate and well-controlled studies in pregnant women. therefore, desonate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. no r

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - azelaic acid (unii: f2vw3d43yt) (azelaic acid - unii:f2vw3d43yt) - azelaic acid .15 g in 1 g - finacea(azelaic acid) foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. none. there are no adequate and well-controlled studies in pregnant women. therefore, finacea foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. dermal embryofetal developmental toxicology studies have not been performed with azelaic acid, 15% foam. oral embryofetal developmental studies were conducted with azelaic acid in rats, rabbits, and cynomolgus monkeys. azelaic acid was administered during the period of organogenesis in all three animal species. embryotoxicity was observed in rats, rabbits, and monkeys at oral doses of azelaic acid that generated some maternal toxicity. embryotoxicity was observed in rats given 2500 mg/kg/day [162 times the maximum recommended human dose (mrhd) based on body surface area (bsa)], rabbits given 150 or 500 mg/kg/day (19 or 65 times the mrhd based on bsa) and cynomolgus monkeys g

Verenigde Staten - Engels - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - sorafenib (unii: 9zoq3tzi87) (sorafenib - unii:9zoq3tzi87) - sorafenib 200 mg - nexavar® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (hcc). nexavar is indicated for the treatment of patients with advanced renal cell carcinoma (rcc). nexavar is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (dtc) that is refractory to radioactive iodine treatment. based on findings from animal studies and its mechanism of action[see clinical pharmacology (12.1)] , nexavar may cause fetal harm when administered to a pregnant woman. there are no available data in pregnant women to inform a drug-associated risk. in animal reproduction studies, oral administration of sorafenib to pregnant rats and rabbits during the period of organogenesis resulted in embryo-fetal toxicities at maternal exposures that were significantly lower than human exposures at the recommended dose of 400 mg twice daily (see data). advise pregnant women and females of reproductive potential of the potential risk to a f